JonathanCJavittMDMPH

Glaucoma Related

CEO and Chairman, NeuroRx, Inc. Professor, Ophthalmology (adj), Johns Hopkins School of Medicine

Dr. Javitt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I work in the areas of Drug Development, Health Information Technology, and Health Policy/Public Health, with a professional background in Ophthalmology, Health Policy, and Health Economics. My career has included a decade as a full-time faculty member at Johns Hopkins and Georgetown Universities in Ophthalmology and Public Policy. Public service in Presidentially-commissioned roles in the Clinton and Bush White House Executive Office of the President, the US Department of Defense, and the National Security Health Policy Center of the Potomac Institute for Policy Studies. Over the past 35 years I have been engaged in a series of healthcare startup companies related to information technology and drug development that have been acquired by Siemens, United Health Group, Aetna, 3M, Quality Systems, Quest, and Biotelemetry, Inc. I am currently engaged full time as CEO of NeuroRx, Inc., a small molecule pharmaceutical company targeting suicidal depression and PTSD.

Johns Hopkins UniversityFellowship, Ophthalmology, 1987 - 1988
Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 1984 - 1987
Harvard Chan School of Public HealthMPH, Kellogg Foundation Fellow in Health Policy and Management, 1983 - 1984
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalInternship, Internal Medicine, 1982 - 1983
Weill Cornell MedicineClass of 1982, MD, Lasdon Award for Excellence in Research
Princeton UniversityAB, Biochemistry, Cum Laude, 1975 - 1978

Alumnus of Merit Harvard School of Public Health, 2015
Edison Award for Innovation The Edison Awards, 2012
Leopold Lecturer Wills Eye Society, 2009
Senior Achievement Award American Academy of Ophthalmology, 2000
President's Leadership Medal Johns Hopkins University, 2000
Guest of Honor New England Ophthalmological Society, 1996
Guest of Honor Japanese Ophthalmological Society, 1996
Prevention of Blindness Lecturer Illinois Society for the Prevention of Blindness, 1995
Crittendon Lecturer University of Melbourne, 1995
Guest of Honor Brazilian Academy of Ophthalmology, 1994
Certificate of Appreciation - Service during Desert Storm US Air Force, 1991
Investigator Award Research to Prevent Blindness, 1991
Honor Award American Academy of Ophthalmology, 1989
International Traveling Fellowship International College of Surgeons, 1982
Harold Lamport Award for Excellence in Research Cornell University Medical College, 1981
Whos Who in Medicine and Healthcare Marquis Whos Who
Fellow (FAAO) American Academy of Ophthalmology
Join now to see all

PubMed

122 citations
Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss.
Jonathan C. Javitt, Zhiyuan Zhou, Richard J. Willke
Ophthalmology. 2007-02-01
200 citations
Model of complications of NIDDM. I. Model construction and assumptions
Richard C. Eastman, Jonathan C. Javitt, William H. Herman, Erik J. Dasbach, Arthur S. Zbrozek
Diabetes Care. 1997-05-01
1731 citations
Global Causes of Blindness and Distance Vision Impairment 1990-2020: A Systematic Review and Meta-Analysis
Seth Flaxman, Rupert R A Bourne, Serge Resnikoff, Peter Ackland, Tasanee Braithwaite
The Lancet. Global Health. 2017-12-01

NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute SuicidalityMay 12th, 2022
NRx Receives Initial Report of Patient Safety and Survival from Right to Try Use of ZYESAMI® (Aviptadil) During Omicron SurgeJanuary 26th, 2022
Lab Notes: Penn Medicine's $14M NIH Grant; NRx Seeks Designation for Drug CandidateDecember 30th, 2021
Join now to see all